# Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026
Canonical URL: https://biopharmsignal.com/news/INGN/inogen-to-report-second-quarter-2026-financial-results-on-august-6-2026-29d58db2
Ticker: INGN
Company: Inogen
Source: Inogen
Published: 2026-07-16 12:30 EST
Original Source URL: /news-events/press-releases/detail/265/inogen-to-report-second-quarter-2026-financial-results-on
## Article Body
BEVERLY, Mass.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN ), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2026 financial results after the market closes on Thursday, August 6, 2026. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET.

Individuals interested in listening to the conference call may do so by dialing:

U.S. domestic callers (877) 841-3961 Non-U.S. callers (201) 689-8589

Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen Investor Relations website. This webcast will also be archived on the website for 6 months.

A replay of the call will be available approximately three hours after the live webcast ends and will be accessible through August 13, 2026. To access the replay, dial (877) 660-6853 or (201) 612-7415 and reference Conference ID: 13761255.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/ , as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Inogen

Inogen, Inc. (Nasdaq: INGN) is a leading global medical technology company offering innovative respiratory products for use in the homecare setting. Inogen supports patient respiratory care by developing, manufacturing, and marketing innovative best-in-class respiratory therapy devices used to deliver care to patients suffering from chronic respiratory conditions. Inogen partners with patients, prescribers, home medical equipment providers, and distributors to make its respiratory therapy products widely available, allowing patients the chance to manage the impact of their disease.

For more information, please visit www.inogen.com .

View source version on businesswire.com: https://www.businesswire.com/news/home/20260716850828/en/

ir@inogen.net

Source: Inogen, Inc.
## Recent Company News
- 2026-07-16 12:30 EST — [Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026](https://biopharmsignal.com/news/INGN/inogen-to-report-second-quarter-2026-financial-results-on-august-6-2026-29d58db2) — Source: Inogen
- 2026-07-01 20:05 EST — [Inogen Announces the Appointment of Andy Reding as Chief Operating Officer](https://biopharmsignal.com/news/INGN/inogen-announces-the-appointment-of-andy-reding-as-chief-operating-officer-4f2d5fcf) — Source: Inogen
- 2026-06-25 13:46 EST — [Inogen Announces First Quarter 2026 Financial Results](https://biopharmsignal.com/news/INGN/inogen-announces-first-quarter-2026-financial-results) — Source: Inogen
- 2026-06-25 13:46 EST — [Inogen Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United States](https://biopharmsignal.com/news/INGN/inogen-announces-the-launch-of-aurora-cpap-masks-for-obstructive-sleep-apnea-in-the-united-states) — Source: Inogen
- 2026-06-25 13:46 EST — [Inogen Announces Preliminary Revenue Results for Fourth Quarter and Full-Year 2025](https://biopharmsignal.com/news/INGN/inogen-announces-preliminary-revenue-results-for-fourth-quarter-and-full-year-2025) — Source: Inogen
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)